More than 60 abstracts will be presented from the ViiV portfolio, including updates from the phase 1 crossover study, the first comparing the acceptability and tolerability of long acting cabotegravir ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback